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ABSTRACT  1 
 2 
Neurotrophin (NT) is important in the survival, maintenance and differentiation of neuronal 3 
tissue, and functions in follicle maturation, tumor growth, angiogenesis and 4 
immunomodulation; however, the expression of NT and its receptors (NTR) in human 5 
placenta and their influence on fetal growth are unclear. Here we investigated the correlation 6 
of NT and NTR in human placenta with uterine environment and fetal growth. TrkB, an NTR, 7 
mRNA was expressed on decidual and villous tissue and increased with gestational age, 8 
localizing in the trophoblast layer and endothelium by immunohistochemistry. Villous TrkB 9 
mRNA was significantly increased in preeclampsia (PE) than in controls and was higher in 10 
the normotensive small for gestational age (SGA) placenta, although it was not significant. It 11 
was also significantly increased in the small twin of discordant twin pregnancies. 12 
Brain-derived neurotrophic factor (BDNF), the main ligand of TrkB, was expressed in 13 
membranous chorion and villous tissue and was significantly higher in maternal plasma in 14 
normotensive SGA and PE than in controls. TrkB mRNA expression was up-regulated on 15 
cultured villous tissue explants and on JEG-3, a choriocarcinoma cell line, by H2O2 treatment. 16 
BDNF decreased apoptotic cells in H2O2-treated JEG-3, indicating that BDNF/TrkB signaling 17 
had anti-apoptotic effects against oxidative stress in JEG-3, suggesting a protective role of 18 
BDNF/TrkB in human villous tissue under unfavorable conditions in utero. 19 
20 
3 
1. Introduction 1 
 2 
Preeclampsia (PE) is a pregnancy-induced disease characterized by elevated blood 3 
pressure and proteinuria after 20 weeks of gestation. The disease is estimated to occur in 4 
3-5 % of pregnancies. Especially in early onset or in severe type, PE is one of the major 5 
causes of maternal mortality because of its severe symptoms (e.g. HELLP syndrome, 6 
eclampsia, renal failure) in addition to causing fetal and neonatal mortality by preterm birth or 7 
intra-uterine growth restriction (IUGR) [1]. A number of studies have suggested possible 8 
mechanisms for the development of PE, including shallow trophoblast invasion and impaired 9 
spiral artery remodeling [2] with subsequent placental hypoperfusion and endothelial 10 
dysfunction. In addition, a variety of factors are thought to contribute to the pathogenesis of 11 
PE: inflammation [3], immune maladaptation [4] and metabolic disorders [5]. Increased 12 
placental apoptosis is reported to be observed in PE and IUGR by a variety of stimuli and 13 
damage, including hypoxia and oxidative stress [6-8]. Despite the progress of clinical and 14 
basic researches, the cause of PE has not been completely elucidated and there is no specific 15 
therapy except for placental delivery. It is known that some growth factors, including 16 
epidermal growth factor (EGF) and insulin-like growth factor (IGF), can rescue trophoblast 17 
apoptosis mediated by cytokine or oxidative stress in vitro [9, 10]. These are examples of the 18 
potent protective mechanisms against various stresses in the feto-maternal environment. 19 
4 
Neurotrophin (NT) is known to be an important factor in the survival, maintenance and 1 
differentiation of neuronal tissue [11-13]. The NT family is composed of nerve growth factor 2 
(NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and 3 
neurotrophin-4 (NT-4). Although they share greater than 80 % identity in their amino acid 4 
structure, each NT interacts with a specific high-affinity tropomyosin-related kinase (Trk) 5 
receptor: NGF activates TrkA, BDNF and NT-4 activate TrkB, and NT-3 activates TrkC [14]. 6 
Recently, NT has also been reported to play an important role in follicle maturation [15], 7 
tumor growth [16], angiogenesis [17-19], immunomodulation [20, 21], inflammation [22, 23], 8 
energy metabolism [24], and so on. Moreover, signaling mediated by BDNF through its 9 
receptor TrkB has been reported to play an important role in embryo implantation, subsequent 10 
placental development and fetal growth by increasing trophoblast cell growth and survival in 11 
mice [25]; therefore, we hypothesized that the NT/NTR system can also play an important 12 
role in the human placenta, as reported in neural or some non-neural tissue. 13 
There are a few reports about their expressions on human placenta and fetal membranes. 14 
Toti et al. reported that NGF was expressed in human placenta [26] and Casciaro et al. 15 
reported that NT-3 was expressed in human placenta [27]; however, the overall expression 16 
profile of NT and its receptors (NTR) on human placenta and their influences on fetal growth 17 
and pathological pregnancy, such as PE and IUGR, are not well elucidated. Here, we tested 18 
the hypothesis that NT and NTR might have an important role in fetal growth and an 19 
5 
unfavorable environment, especially in the feto-maternal interface. The aim of this study was 1 
to investigate the expression profile of NT/NTR in human placenta and maternal plasma, 2 
especially in association with PE and/or fetal growth, and to assess their roles in the 3 
pathological environment. 4 
 5 
2. Materials and methods 6 
 7 
2.1. Patient characteristics and tissue collection 8 
 9 
We collected normal villous tissues in the first (6 to 13 weeks of gestation, n = 11) and 10 
second trimester (16 to 25 weeks of gestation, n = 7), including 6 legal abortions and 1 preterm 11 
birth. Pathological placentas in the third trimester included 15 complicated with PE and 11 12 
with normotensive SGA (small for gestational age). Sixteen uncomplicated normal controls 13 
were also collected. The clinical characteristics are shown in Table 1. PE was defined as 14 
maternal systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg in 2 15 
consecutive measurements, with an interval of 6 h, and proteinuria ≥300 mg per 24 h after 20 16 
weeks of gestation. SGA was defined as birth weight less than the 10th percentile. The numbers 17 
of PE with SGA and PE without SGA were 11 and 4, respectively. In addition, we collected 18 
villous tissues from dichorionic twins as a separate group as they share the same maternal and 19 
6 
uterine environment. Seven discordant twins and 5 concordant twins were included in this 1 
study. The discordant twin was defined as having discordancy of more than 15 % difference 2 
in neonatal birth weight. Villous tissues were taken from the central part of the placenta and 3 
were free of visible infarction or calcification, and separated amnion and membranous chorion 4 
and decidua of the basal plate were collected within 20 min after Cesarean section without labor. 5 
After brief rinsing in saline, these tissues were quickly frozen in liquid nitrogen and stored at 6 
-80 ˚C until the experiment. Informed consent was obtained from each patient before sampling. 7 
The protocol was approved by the local ethics committee of Kyoto University Graduate School 8 
of Medicine. 9 
 10 
2.2. Real-time quantitative PCR 11 
 12 
Total RNA was extracted from the samples using the QIAGEN RNeasy Mini kit 13 
(QIAGEN, Germantown, MD) according to the manufacturer’s instructions. Five micrograms 14 
of total RNA were reversed into cDNA using a First-Strand cDNA Synthesis Kit (GE 15 
Healthcare, Little Chalfont, UK). Primers for the genes examined (Table 2) were designed 16 
using GeneFisher 2 software (Bielefeld University Bioinformatics Service, Bielefeld, 17 
Germany). The primers for human GAPDH were purchased from Applied Biosystems (Foster 18 
City, CA). Quantitative PCR (qPCR) amplification was performed with a final volume of 20 19 
7 
µl containing 33 ng template cDNA, 0.4 µM of each primer, and 10 µl SYBR Premix Ex Taq 1 
II (Takara Bio, Otsu, Japan). The reaction was performed using the ABI PRISM 7000 2 
Sequence Detection System (Applied Biosystems) with the following PCR conditions: 95 ˚C 3 
for 10 sec, followed by 95 ˚C for 5 sec and 60 ˚C for 31 sec, repeated for 40 cycles. For 4 
dissociation after PCR amplification, the protocol included slow heating from 60 to 95 ˚C to 5 
ensure amplification specificity. The gene expression was estimated using the 2
-ΔCt
 method. Ct 6 
values were used to read off relative RNA amounts. The values of NT and NTR mRNA 7 
expression were obtained by the relative value for GAPDH mRNA. All samples were run in 8 
duplicate, and quantitative detection was averaged. 9 
 10 
2.3. Immunohistochemistry 11 
 12 
Immunohistochemical staining was conducted by the streptavidin-biotin-peroxidase 13 
method. Formalin-fixed, paraffin-embedded specimens of uncomplicated third trimester 14 
pregnancies were cut into 4 µm-thick sections. The tissue sections were deparaffinized in 15 
xylene (3×10 min) and dehydrated through graded alcohol (99 %, 80 % and 70 %) to water. 16 
Tissue samples were heated to retrieve antigens in Tris-EDTA buffer (pH 9.0) at 120 ˚C for 5 17 
min. Endogenous peroxidase activity was blocked using 0.3 % H2O2. The sections were 18 
incubated with mouse monoclonal antibody against TrkB (diluted 1:100; R&D Systems, 19 
8 
Minneapolis, MN, code MAB397) and rabbit polyclonal antibody against BDNF (diluted 1 
1:100; Santa Cruz Biotechnology, Santa Cruz, CA, code SC-546) overnight at 4 ˚C. 2 
Corresponding nonspecific IgG (Dako, Carpinteria, CA) was used as a negative control and 3 
processed in parallel. They were then incubated with biotinylated rabbit anti-mouse Ig 4 
secondary antibody for TrkB or with biotinylated goat anti-rabbit Ig for BDNF (Nichirei, 5 
Tokyo, Japan), followed by incubation with streptavidin-peroxidase complex solution for 30 6 
min at room temperature (RT). Peroxidase activity was visualized by treatment with 7 
diaminobenzidine. Finally, the nuclei of sections were counterstained with Mayer’s 8 
hematoxylin and observed under a microscope (Olympus, Tokyo, Japan). 9 
 10 
2.4. Plasma assays 11 
 12 
Maternal blood from uncomplicated pregnancies was obtained from the first (n = 9), 13 
second (n = 7) or third (n = 11) trimester. Samples from normotensive SGA (n = 6) and PE (n 14 
= 12) patients were taken in the third trimester after the onset of disease. Umbilical blood was 15 
obtained at the time of Cesarean section in the third trimester, including normal controls (n = 16 
8), PE (n = 5) and normotensive IUGR (n = 2). The blood was sampled into heparinized tubes, 17 
plasma separated by centrifugation at 3000 rpm for 30 min, and stored at -20 ˚C until analysis. 18 
Plasma BDNF was measured using the human BDNF enzyme-linked immunosorbent assay 19 
9 
(ELISA) kit (R&D Systems) in duplicate each sample as instructed by the manufacturer. 1 
According to the manufacturer’s protocol, coefficients of variation for BDNF ELISA were as 2 
follows: intra-assay precision and inter-assay precision were 3.8-6.2 % and 7.6-11.3 %, 3 
respectively. 4 
 5 
2.5. Tissue and cell culture and oxidative stress 6 
 7 
Placental villous tissues were collected from normal term pregnancies (n = 10) delivered 8 
by elective Cesarean section. Tissues were taken from midway between the chorionic and basal 9 
plates and were free of visible infraction or calcification. After brief rinsing in ice-cold 10 
phosphate-buffered saline (PBS), tissues were placed in ice-cold RPMI 1640 medium (Nacalai 11 
Tesque, Kyoto, Japan). Samples were taken to the laboratory and processed within 30 min. 12 
They were further dissected into small pieces (about 2-3 mm in diameter), and 3 fragments 13 
were placed in 6-well plates with 3 ml culture medium (RPMI 1640 containing streptomycin, 14 
penicillin, and 10 % fetal calf serum) per well. Subsequently, tissues were incubated with or 15 
without H2O2 (100 µM) for 2 h in a culture incubator with 5 % CO2/95 % air at 37 ˚C. Placental 16 
villous explants were then collected and stored at -80 ˚C. H2O2 concentration was determined 17 
according to a previous report [9] showing that 100 µM H2O2 was effective to increase 18 
apoptosis in the placental explant culture.  19 
10 
The JEG-3 (HTB-36) choriocarcinoma cell line was obtained from the American Type 1 
Culture Collection (Manassas, VA). The cells were maintained in RPMI medium containing 2 
streptomycin, penicillin, and 10 % fetal calf serum at 37 ˚C with 5 % CO2 / 95 % air. JEG-3 3 
were incubated for 2 h with or without H2O2 (5 µM) and harvested. A marked number of 4 
JEG-3 cells died in a concentration of 100 µM. After preliminary experiments of 1, 5 and 50 5 
µM, we selected 5 µM as an appropriate concentration for the cell culture that showed 6 
increased apoptosis but less cell death.   7 
 TrkB mRNA in these tissues and cell samples were measured by qPCR. The amount of 8 
TrkB mRNA from 3 wells was averaged and the experiments were repeated 6 times. 9 
 10 
2.6. Apoptosis analysis  11 
 12 
Apoptosis analysis was assessed using the Annexin V-FITC Apoptosis Detection kit I (BD 13 
Biosciences, San Jose, CA) by a fluorescence-activated cell sorter (FACS). Annexin V 14 
identifies cells in early apoptosis by detecting externalized phosphatidylserine, and propidium 15 
iodide (PI) identifies necrotic or late apoptotic cells that have lost plasma membrane integrity. 16 
JEG-3 cells on 6 cm culture dishes were administered 50 ng/ml recombinant human (rh) 17 
BDNF (PeproTech, Rocky Hill, NJ) 24 h prior to H2O2 (5 µM) treatment. Vehicle only was 18 
used as a control. This was selected according to the manufacturer’s instructions depending 19 
11 
on previous reports [28, 29]. We did not perform a dose response experiment but performed 1 
the experiment once using 10 ng/ml, which was less effective than 50 ng/ml. 2 
For the blocking experiment, 100 nM k252a (inhibitor of pan Trk signaling; Calbiochem, 3 
Darmstadt, Germany) or k252b, which is almost equipotent to k252a but without inhibiting 4 
activity, was added just prior to rhBDNF (50 ng/ml) administration, followed by H2O2 5 
treatment 24 h later. After incubation for 2 h with H2O2, the cells were harvested by 6 
trypsin-EDTA and centrifuged at 3000 rpm for 10 min. The cells were washed twice with PBS 7 
(containing 0.2 % fetal calf serum) at RT, resuspended in 100 µl of 1× binding buffer 8 
supplemented with 5 µl FITC conjugated Annexin V and 2 µl PI, and incubated at RT in the 9 
dark for 15 min according to the manufacturer’s instructions. Following the addition of 400 µl 10 
of 1× binding buffer, stained cells were kept on ice and subjected immediately to FACS 11 
analysis using a FACSCalibur flow cytometer with CellQuest software (BD, Franklin Lakes, 12 
NJ). The cell debris and small particles were excluded from analysis. When cells were double 13 
stained, 4 different groups of cells were observed: both negative cells (Annexin V (-) / PI (-)) 14 
were defined as viable cells, cells stainable with Annexin V but not with PI were early 15 
apoptotic cells, both positive cells were late apoptotic or necrotic cells, and PI (+) -only cells 16 
were debris of dead cells.  17 
 18 
2.7. Cell proliferation assay (WST assay)  19 
 20 
12 
WST assay was performed using Cell Count Reagent SF (Nacalai, Kyoto, Japan) 1 
according to the manufacturer’s protocol to examine the proliferation of JEG-3 cells. JEG-3 2 
cells on 96-well plates were cultured with rhBDNF (50 ng/ml) for 24 h or 48 h. Vehicle-only 3 
was used as a control. The media were changed to 110 µl fresh medium containing 10 µl 4 
Reagent SF. After 4 h, the absorbance of the media at 450 nm was measured using an Emax 5 
microplate reader (Molecular Devices, Tokyo, Japan).  6 
 7 
2.8. Statistical analysis 8 
 9 
The results of normally distributed continuous variables are expressed as the mean ± 10 
SEM (range), while those with skewed distribution were expressed as the median value with 11 
[interquartile range]. Continuous variables were analyzed by the Wilcoxon t test, 12 
Mann-Whitney U test and Kruskal-Wallis H test, as appropriate. Pearson’s correlation 13 
coefficient was used for evaluation of a possible association between neonatal birth weight 14 
and TrkB expression in villous tissue. A p value of < 0.05 denoted statistical significance. 15 
Statistical analyses were performed using Prism 3.0 (GraphPad Software, La Jolla, CA).  16 
 17 
3. Results 18 
 19 
13 
3.1. Patient characteristics 1 
 2 
The features of the patients are shown in Table 1. Gestational age at delivery was lower 3 
in the PE group than in controls. Neonatal and placental weights were lighter in the 4 
normotensive SGA and PE group than in controls. Among 15 patients with PE, 11 were 5 
complicated with SGA and 4 were not; 5 were early onset type and 10 were late onset type.  6 
 7 
3.2. NT and NTR mRNA expression in villous tissue and fetal membranes  8 
 9 
The expression profile of NT and NTR mRNA was investigated in separate fetal 10 
membranes (amnion, membranous chorion, and decidua) and villous tissue samples in the 3rd 11 
trimester (Fig. 1A). Among 4 NTs, NGF, BDNF, and NT-3 were detected in the amnion and 12 
membranous chorion, but there was no significant difference between these tissues. NT-4 was 13 
less expressed in those tissues. The BDNF mRNA level was higher in the membranous chorion 14 
and villous tissue than amnion and decidua, although they did not reach statistical significance 15 
(Fig. 1A). Among 3 NTRs, the expression of TrkB in decidua and villous tissue was higher 16 
than in other tissues and other NTRs; however, they were not statistically significant (Fig. 1B). 17 
TrkB expression in villous tissue was significantly increased in the second and third trimesters 18 
compared to the first trimester (Fig. 1C).  19 
14 
 1 
3.3. Localization of BDNF and TrkB  2 
 3 
In the third trimester placenta, BDNF immunostaining was observed in the membranous 4 
chorion (Fig. 2A), trophoblast layer and endothelium (Fig. 2B), whereas TrkB 5 
immunostaining was observed in the decidua (Fig. 2D), trophoblast layer and endothelium 6 
(Fig. 2E). In the trophoblast layer, TrkB was confirmed to localize in both cytotrophoblast 7 
cells and syncytiotrophoblast cells in the first and second trimesters (Fig. 2G and H). The 8 
localization of TrkB was not different throughout the gestational age (Fig. 2G, H and E) and 9 
appeared similar even in PE (Fig. 2I).  10 
 11 
3.4. Placental TrkB mRNA expression according to pathological status 12 
 13 
Among 42 samples, including normal term controls, normotensive SGA and PE, TrkB 14 
mRNA was significantly higher in PE placentas than in normal term controls (Fig. 3A). There 15 
was no significant difference between PE with SGA (0.85 [0.53-0.11] ×10
-2
, n = 11) and PE 16 
without SGA (0.47 [0.38-0.94] ×10
-2
, n = 4). The increase of TrkB in normotensive SGA was 17 
not significant. Pearson’s correlation tests of 42 samples demonstrated that TrkB expression 18 
was reversely correlated with neonatal birth weight (Fig. 3B). 19 
15 
 1 
3.5. TrkB mRNA expression in discordant twin placentas 2 
 3 
Theoretically, dichorionic twins share the same maternal environment and their genomes 4 
are different; therefore, the difference in TrkB between discordant dichorionic twin placentas 5 
was thought to be regulated by the placental environment, which causes fetal growth 6 
discordancy. TrkB was significantly higher in villous tissues of small twins than their co-twins 7 
(Fig. 3C), whereas it was not different between concordant twins (Fig. 3D). Conversely, 8 
BDNF was not different in discordant twins (data not shown). 9 
 10 
3.6. Plasma BDNF level 11 
 12 
Maternal plasma BDNF levels were significantly higher in the normotensive SGA and PE 13 
group than in non-complicated pregnant women in the third trimester (Fig. 3E). Gestational 14 
age did not affect plasma BDNF levels (first: 262.8 pg/ml [130.6-352.7], second: 236.4 pg/ml 15 
[155.5-1609.8] and third: 623.8 pg/ml [330.9-1024.0]). In umbilical plasma, BDNF levels 16 
were not influenced by the pathological status, such as in PE, normotensive SGA and 17 
discordant twins (data not shown). 18 
 19 
16 
3.7. Effect of BDNF/TrkB against oxidative stress in vitro 1 
 2 
The expression of TrkB in villous explants was significantly increased when cultured 3 
with 100 µM H2O2 for 2 h (Fig. 4A). TrkB on JEG-3 cells was also significantly increased 4 
with 5 µM H2O2 for 2 h (Fig. 4B).  5 
In the FACS experiment, JEG-3 cells were evaluated by double-staining with Annexin V 6 
and PI: both negative cells were defined as viable, Annexin V positive / PI negative were 7 
early apoptotic, and both positive cells were late apoptotic or necrotic. The cells were divided 8 
into these populations by the lines indicated. Representative FACS plots are shown in the 9 
presence or absence of H2O2 and rhBDNF (Fig. 5A-C). The level of late apoptotic or necrotic 10 
cells was significantly increased at 2 h with 5 µM of H2O2 (Fig. 5B and D). When cells were 11 
pretreated with rhBDNF (50 ng/ml) 24 h prior to H2O2 treatment, late apoptotic or necrotic 12 
cells were not increased even with H2O2 treatment (Fig. 5C and D). On the other hand, viable 13 
cells were significantly decreased by H2O2 treatment, whereas rhBDNF pre-treatment 14 
diminished the decrease of viable cells (Fig. 5B, C and F). The relative cell number in each 15 
group was evaluated as the ratio to those in the group without H2O2 and rhBDNF treatment.  16 
In the culture model of JEG-3 with H2O2 and rhBDNF, k252a (inhibitor of pan Trk) 17 
treatment significantly induced late apoptosis or necrosis but k252b (equipotent to k252a 18 
without inhibiting activity) caused no marked change (Fig. 5G). 19 
17 
As for early apoptosis, a similar result was observed in that k252a treatment significantly 1 
induced apoptotic cells (Fig. 5H). On the other hand, viable cells were significantly decreased 2 
by k252a administration compared to k252b treatment (Fig. 5I). These results were evaluated 3 
as the relative cell number compared to those treated with H2O2 and rhBDNF without k252a 4 
and k252b. 5 
 6 
3.8. Proliferation of JEG-3 by rhBDNF 7 
 8 
Cell proliferation assay revealed no statistically significant difference in the growth of 9 
JEG-3 cultured with rhBDNF compared with vehicle only. The absorbance of the media at 10 
450 nm was as follows: 0.086 [0.075-0.099] with rhBDNF vs. 0.118 [0.111-0.130] with 11 
vehicle only for 24 h, 0.263 [0.247-0.260] with rhBDNF vs. 0.349 [0.319-0.377] with vehicle 12 
only for 48 h (n = 4). 13 
 14 
4. Discussion 15 
 16 
In the present study, we investigated the expression profile of NT and NTR and their 17 
potential roles in human pregnancy. We present a detailed expression profile for the first time 18 
for NT and NTR in human placenta and the fetal membrane. We also investigated the 19 
18 
regulation of these expressions in association with PE and/or fetal growth. We then assessed 1 
their effects in the pathological environment in vitro. The expressions of NGF, BDNF and 2 
NT-3 mRNAs were detected in these tissues, although no significant difference was detected 3 
among the tissues examined. On the other hand, we demonstrated the expression of TrkB on 4 
villous tissue and decidua among 4 NTRs. TrkB expression increased with gestational age and 5 
was up-regulated in PE patients. These findings strongly suggest a relationship between TrkB 6 
and the pathological status in the placenta; thus, we focused on BDNF, the main ligand of 7 
TrkB among the NTs. Both BDNF and TrkB in villous tissue were localized in the trophoblast 8 
layer as well as the endothelium, which is consistent with previous reports [18, 19]. BDNF 9 
was detected in maternal plasma and its level was significantly higher in normotensive SGA 10 
and PE patients than normal controls in the third trimester. These findings suggest that the 11 
BDNF/TrkB system may be activated at the feto-maternal interface under unfavorable 12 
conditions during pregnancy.  13 
We also demonstrated that the expression of TrkB was up-regulated in PE despite the 14 
presence or absence of SGA and there was no significant difference between these two groups. 15 
We did not detect significant up-regulation of TrkB in SGA placenta; however, Mayeur et al. 16 
reported that mRNA expression of TrkB was significantly increased in human IUGR placenta 17 
[30]. This discrepancy seems to be due to the severity of IUGR; the patients in Mayeur’s 18 
report were more severely affected than our patients. Villous TrkB expression correlated with 19 
19 
neonatal birth weight and was significantly increased in the smaller twin of discordant twins; 1 
therefore, the increase of TrkB expression in human placenta may be related to fetal growth.  2 
NTs are known to be an important factor in the survival, maintenance and differentiation 3 
of neuronal tissue [11-13]. Although TrkB
-/-
 mice were not embryonically lethal but showed 4 
neuronal deficiencies in the central and peripheral nervous systems and neonatal death due to 5 
insufficient feeding activity [31], the effect of TrkB
-/- 
on the placenta was unclear in this 6 
article, but we suppose that TrkB is not essential for placental development in normal 7 
pregnancy but functions under unfavorable conditions. 8 
As maternal BDNF reaches the fetal brain through the utero-placental barrier, it 9 
contributes to development in mice [32]. Thus, previous studies on NTs during pregnancy 10 
mostly focused on the effect on the fetal nervous system; for example, Marx reported that 11 
NTs were detectable in human amniotic fluid and their decreased levels may reflect 12 
abnormalities in the fetal brain in utero [33]. Although the anti-apoptotic effect of NTs on 13 
neuronal and non-neuronal tissues, such as endothelial cells, has already been reported [34], 14 
we showed in the present study that BDNF administration decreased the rate of apoptotic or 15 
necrotic cells in H2O2- treated JEG-3 cells, which suggests that BDNF/TrkB signaling also has 16 
an anti-apoptotic effect on trophoblast cells. Placental apoptosis increased with placental 17 
growth according to gestational age even in normal development [35]; however, it was marked 18 
in complicated pregnancies, such as hydatidiform mole, PE and IUGR [6-8, 36, 37]. An 19 
20 
increased number of syncytial knots were observed in PE and IUGR placentas and could be 1 
replicated in vitro by reactive oxygen species (ROS) or hypoxia [38]. Our in vitro findings 2 
suggest that BDNF/TrkB can play a protective role in the placenta against oxidative stress by 3 
reducing or slowing the increase of apoptotic cells in PE or SGA. 4 
Although the precise mechanism of the anti-apoptotic effects of BDNF/TrkB has not 5 
been elucidated, some reports have demonstrated relationships between BDNF/TrkB and 6 
some important factors associated with PE. BDNF induces vascular endothelial growth factor 7 
(VEGF) expression via hypoxia-inducible factor-1 alpha in neuroblastoma cells [39] and may 8 
act on angiogenesis through VEGF. It is known that VEGF and placental growth factor 9 
(PlGF) and their receptors play important roles in PE. The increase of circulating soluble 10 
fms-like tyrosine kinase-1 (sFlt-1), which is a soluble receptor of VEGF, is associated with 11 
the symptoms of PE, partly by inhibiting the VEGF effect [40, 41]; therefore, we speculate 12 
that BDNF might supplement the impaired VEGF system. 13 
Recent studies demonstrated a possible relationship between the stress-induced steroid 14 
hormone, glucocorticoid, and BDNF/TrkB, which has a neuroprotective effect [42]. It was 15 
also reported that stress induces BDNF in rat submandibular glands [43]; therefore, 16 
BDNF/TrkB may function to contribute to the maintenance of an impaired placenta in a 17 
stressful environment. Accordingly, it will be valuable to investigate the network or balance 18 
of various factors, including BDNF/TrkB as well as VEGF, sFlt-1 and so on in PE or IUGR 19 
21 
patients. 1 
We showed elevated levels of BDNF in the maternal plasma of PE patients. As the 2 
BDNF level in maternal blood is reported to be consistent during normal pregnancy [44], 3 
which is compatible with our results, we found that BDNF levels are up-regulated in the 4 
plasma of PE patients. BDNF is reported to be secreted from endothelial cells, macrophages 5 
and monocytes [45], and platelets contain a large amount of BDNF and release it when 6 
activated [46]. It will be interesting to investigate the source of increased BDNF and the 7 
regulation of its secretion in PE patients. 8 
In conclusion, we have demonstrated that placental TrkB and maternal BDNF are 9 
up-regulated in the pathological environment, such as PE and small twins. BDNF/TrkB 10 
signaling may have an anti-apoptotic effect in response to oxidative stress on the 11 
choriocarcinoma cell line, and suggests a protective role of BDNF/TrkB in villous tissue 12 
under stress-induced unfavorable conditions. Further investigation of the physiology and 13 
relationship among the responsible factors, including BDNF/TrkB signaling, in maternal and 14 
fetal units may reveal the mechanism of placental maintenance in a stressful environment, 15 





This work was supported by Grants-in-Aid for Scientific Research from the Ministry of 3 
Education, Science, Culture and Sports, Japan (No. 21592096). The authors are grateful to 4 






[1] Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005;365:785-99. 3 
[2] Kaufmann P, Black S, Huppertz B. Endovascular trophoblast invasion: implications for 4 
the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod 5 
2003;69:1-7. 6 
[3] Challis JR, Lockwood CJ, Myatt L, Norman JE, Strauss JF 3rd, Petraglia F. Inflammation 7 
and pregnancy. Reprod Sci 2009;16:206-15. 8 
[4] Saito S, Sakai M, Sasaki Y, Nakashima A, Shiozaki A. Inadequate tolerance induction 9 
may induce pre-eclampsia. J Reprod Immunol 2007;76:30-9. 10 
[5] Seely EW, Solomon CG. Insulin resistance and its potential role in pregnancy-induced 11 
hypertension. J Clin Endocrinol Metab 2003;88:2393-8. 12 
[6] Smith SC, Baker PN, Symonds EM. Increased placental apoptosis in intrauterine growth 13 
restriction. Am J Obstet Gynecol 1997;177:1395-401. 14 
[7] Sharp AN, Heazell AE, Crocker IP, Mor G. Placental Apoptosis in Health and Disease. 15 
Am J Reprod Immunol 2010;64:159-69. 16 
[8] Allaire AD, Ballenger KA, Wells SR, McMahon MJ, Lessey BA. Placental apoptosis in 17 
preeclampsia. Obstet Gynecol 2000;96:271-6. 18 
[9] Moll SJ, Jones CJ, Crocker IP, Baker PN, Heazell AE. Epidermal growth factor rescues 19 
24 
trophoblast apoptosis induced by reactive oxygen species. Apoptosis 2007;12:1611-22. 1 
[10] Smith S, Francis R, Guilbert L, Baker PN. Growth factor rescue of cytokine mediated 2 
trophoblast apoptosis. Placenta 2002;23:322-30. 3 
[11] Nguyen N, Lee SB, Lee YS, Lee KH, Ahn JY. Neuroprotection by NGF and BDNF 4 
against neurotoxin-exerted apoptotic death in neural stem cells are mediated through Trk 5 
receptors, activating PI3-kinase and MAPK pathways. Neurochem Res 2009;34:942-51. 6 
[12] Conover JC, Yancopoulos GD. Neurotrophin regulation of the developing nervous 7 
system: analyses of knockout mice. Rev Neurosci 1997;8:13-27. 8 
[13] Barde YA. Trophic factors and neuronal survival. Neuron 1989;2:1525-34. 9 
[14] Barbacid M. Structural and functional properties of the TRK family of neurotrophin 10 
receptors. Ann N Y Acad Sci 1995;766:442-58. 11 
[15] Seifer DB, Feng B, Shelden RM, Chen S, Dreyfus CF. Brain-derived neurotrophic factor: 12 
a novel human ovarian follicular protein. J Clin Endocrinol Metab 2002;87:655-9. 13 
[16] Thiele CJ, Li Z, McKee AE. On Trk--the TrkB signal transduction pathway is an 14 
increasingly important target in cancer biology. Clin Cancer Res 2009;15:5962-7. 15 
[17] Kraemer R, Hempstead BL. Neurotrophins: novel mediators of angiogenesis. Front 16 
Biosci 2003;8:s1181-6. 17 
[18] Kermani P, Hempstead B. Brain-derived neurotrophic factor: a newly described mediator 18 
of angiogenesis. Trends Cardiovasc Med 2007;17:140-3. 19 
25 
[19] Caporali A, Emanueli C. Cardiovascular actions of neurotrophins. Physiol Rev 1 
2009;89:279-308. 2 
[20] Scuri M, Samsell L, Piedimonte G. The role of neurotrophins in inflammation and 3 
allergy. Inflamm Allergy Drug Targets 2010;9:173-80. 4 
[21] Vega JA, Garcia-Suarez O, Hannestad J, Perez-Perez M, Germana A. Neurotrophins and 5 
the immune system. J Anat 2003;203:1-19. 6 
[22] Schulte-Herbruggen O, Nassenstein C, Lommatzsch M, Quarcoo D, Renz H, Braun A. 7 
Tumor necrosis factor-alpha and interleukin-6 regulate secretion of brain-derived 8 
neurotrophic factor in human monocytes. J Neuroimmunol 2005;160:204-9. 9 
[23] Hahn C, Islamian AP, Renz H, Nockher WA. Airway epithelial cells produce 10 
neurotrophins and promote the survival of eosinophils during allergic airway 11 
inflammation. J Allergy Clin Immunol 2006;117:787-94. 12 
[24] Rios M, Fan G, Fekete C, Kelly J, Bates B, Kuehn R. Conditional deletion of 13 
brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity. 14 
Mol Endocrinol 2001;15:1748-57. 15 
[25] Kawamura K, Kawamura N, Sato W, Fukuda J, Kumagai J, Tanaka T. Brain-derived 16 
neurotrophic factor promotes implantation and subsequent placental development by 17 
stimulating trophoblast cell growth and survival. Endocrinology 2009;150:3774-82. 18 
[26] Toti P, Ciarmela P, Florio P, Volpi N, Occhini R, Petraglia F. Human placenta and fetal 19 
26 
membranes express nerve growth factor mRNA and protein. J Endocrinol Invest 1 
2006;29:337-41. 2 
[27] Casciaro A, Arcuri F, Occhini R, Toti MS, De Felice C, Toti P. Expression of Placental 3 
Neurotrophin-3 (NT-3) in Physiological Pregnancy, Preeclampsia and Chorioamnionitis. 4 
Clin Med Pathol 2009;2:9-15. 5 
[28] Pearse RN, Swendeman SL, Li Y, Rafii D, Hempstead BL. A neurotrophin axis in  6 
myeloma: TrkB and BDNF promote tumor-cell survival. Blood 2005;105:4429-36. 7 
[29] Sanchez-Munoz I, Sanchez-Franco F, Vallejo M, Fernandez A, Palacios N,  8 
Fernandez M. Regulation of somatostatin gene expression by brain derived neurotrophic 9 
factor in fetal rat cerebrocortical cells. Brain Res 2011;1375:28-40. 10 
[30] Mayeur S, Silhol M, Moitrot E, Barbaux S, Breton C, Gabory A. Placental BDNF/TrkB 11 
Signaling System is Modulated by Fetal Growth Disturbances in Rat and Human. 12 
Placenta 2010;31:785-91. 13 
[31] Klein R, Smeyne RJ, Wurst W, Long LK, Auerbach BA, Joyner AL. Targeted disruption 14 
of the trkB neurotrophin receptor gene results in nervous system lesions and neonatal 15 
death. Cell 1993;75:113-22. 16 
[32] Kodomari I, Wada E, Nakamura S, Wada K. Maternal supply of BDNF to mouse fetal 17 
brain through the placenta. Neurochem Int 2009;54:95-8. 18 
[33] Marx CE, Vance BJ, Jarskog LF, Chescheir NC, Gilmore JH. Nerve growth factor, 19 
27 
brain-derived neurotrophic factor, and neurotrophin-3 levels in human amniotic fluid. Am 1 
J Obstet Gynecol 1999;181:1225-30. 2 
[34] Kim H, Li Q, Hempstead BL, Madri JA. Paracrine and autocrine functions of 3 
brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in 4 
brain-derived endothelial cells. J Biol Chem 2004;279:33538-46. 5 
[35] Smith SC, Baker PN, Symonds EM. Placental apoptosis in normal human pregnancy. 6 
Am J Obstet Gynecol 1997;177:57-65. 7 
[36] Crocker IP, Cooper S, Ong SC, Baker PN. Differences in apoptotic susceptibility of 8 
cytotrophoblasts and syncytiotrophoblasts in normal pregnancy to those complicated with 9 
preeclampsia and intrauterine growth restriction. Am J Pathol 2003;162:637-43. 10 
[37] Ishihara N, Matsuo H, Murakoshi H, Laoag-Fernandez JB, Samoto T, Maruo T. 11 
Increased apoptosis in the syncytiotrophoblast in human term placentas complicated by 12 
either preeclampsia or intrauterine growth retardation. Am J Obstet Gynecol 13 
2002;186:158-66. 14 
[38] Heazell AE, Moll SJ, Jones CJ, Baker PN, Crocker IP. Formation of syncytial knots is 15 
increased by hyperoxia, hypoxia and reactive oxygen species. Placenta 2007;28 Suppl 16 
A:S33-40. 17 
[39] Nakamura K, Martin KC, Jackson JK, Beppu K, Woo CW, Thiele CJ. Brain-derived 18 
neurotrophic factor activation of TrkB induces vascular endothelial growth factor 19 
28 
expression via hypoxia-inducible factor-1alpha in neuroblastoma cells. Cancer Res 1 
2006;66:4249-55. 2 
[40] Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S. Excess placental soluble 3 
fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, 4 
and proteinuria in preeclampsia. J Clin Invest 2003;111:649-58. 5 
[41] Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF. Circulating angiogenic 6 
factors and the risk of preeclampsia. N Engl J Med 2004;350:672-83. 7 
[42] Jeanneteau F, Garabedian MJ, Chao MV. Activation of Trk neurotrophin receptors by 8 
glucocorticoids provides a neuroprotective effect. Proc Natl Acad Sci U S A 9 
2008;105:4862-7. 10 
[43] Tsukinoki K, Saruta J, Sasaguri K, Miyoshi Y, Jinbu Y, Kusama M. Immobilization 11 
stress induces BDNF in rat submandibular glands. J Dent Res 2006;85:844-8. 12 
[44] Malamitsi-Puchner A, Economou E, Rigopoulou O, Boutsikou T. Perinatal changes of 13 
brain-derived neurotrophic factor in pre- and fullterm neonates. Early Hum Dev 14 
2004;76:17-22. 15 
[45] Rost B, Hanf G, Ohnemus U, Otto-Knapp R, Groneberg DA, Kunkel G. Monocytes of 16 
allergics and non-allergics produce, store and release the neurotrophins NGF, BDNF and 17 
NT-3. Regul Pept 2005;124:19-25. 18 
[46] Lommatzsch M, Zingler D, Schuhbaeck K, Schloetcke K, Zingler C, Schuff-Werner P 19 
29 
and Virchow JC. The impact of age, weight and gender on BDNF levels in human 1 




Figure Legends  1 
 2 
Fig. 1. Expression of neurotrophins (NTs) and neurotrophin receptors (NTRs) in human 3 
placenta. Relative mRNA expression of NTs (A) and NTRs (B) in fetal membranes and 4 
villous tissues (n = 4) in normal term pregnancy. (C) TrkB mRNA expression on villous tissue 5 
in the first, second and third trimesters (n = 11, 7 and 16, respectively). * p < 0.05, **p < 6 
0.001. Each mRNA expression was normalized by GAPDH. Lines within the boxes represent 7 
the median value; top and bottom lines of the boxes represent 25th and 75th percentiles, and 8 
upper and lower bars outside the box represent 90th and 10th percentiles, respectively. 9 
 10 
Fig. 2. Localized expression of BDNF and TrkB in human placenta.  11 
Representative immunohistochemical staining of BDNF (A-C) and TrkB (D-I) in fetal 12 
membrane (A, D), villous tissue (B, C, E, F) in normal term placenta, first trimester placenta 13 
(G), second trimester placenta (H), and preeclamptic placenta (I). (C and F) Negative control 14 
for BDNF and TrkB, respectively. Arrowhead: trophoblast layer; arrow: endothelium. 15 
 16 
Fig. 3. TrkB mRNA expressions and plasma BDNF levels in the pathological status.  17 
(A) TrkB mRNA expression in villous tissue in normal term control (n = 16), normotensive 18 
SGA (n = 11) and PE (n = 15). (B) Correlation between neonatal birth weight and TrkB 19 
expression in villous tissue of 42 patients. SD: standard deviation, r: correlation coefficient. 20 
31 
TrkB mRNA expression in villous tissue of discordant twins (C, n = 7) and concordant twins 1 
(D, n = 5). (E) Maternal plasma BDNF levels in third trimester in normal pregnancies (n = 11), 2 
normotensive SGA (n = 6) and PE (n = 12). The mRNA expressions were normalized by 3 
GAPDH. * p < 0.05, ** p < 0.01 4 
 5 
Fig. 4. Expression of TrkB mRNA under oxidative stress in vitro.  6 
TrkB mRNA in villous explants (A, n = 10) and JEG-3 cells (B, n = 6) cultured with or 7 
without H2O2 for 2 hours. The mRNA expressions were normalized by GAPDH. * p < 0.05, 8 
** p < 0.01 9 
 10 
Fig. 5. Effect of BDNF/TrkB signaling against oxidative stress on JEG-3 cells.  11 
Induction of apoptosis by H2O2 and the effect of BDNF on JEG-3 cells were examined by 12 
FACS (n = 6). (A-C) Representative FACS plots by double-staining with Annexin V and PI. 13 
Non-treatment group (A) treated with H2O2 (B) and H2O2 plus rhBDNF (C). Positive cells for 14 
both were defined as late apoptosis or necrosis (D, G); Annexin V positive/PI negative as 15 
early apoptosis (E, H); both negative as viable (F, I). (D-F) Relative number of JEG-3 cells 16 
treated with H2O2 (lane 2) and H2O2 plus rhBDNF (lane 3) compared to non-treatment group 17 
(lane 1). (G-I) Inhibition of the anti-apoptotic effect of BDNF by k252a, an inhibitor of Trk. 18 
Relative number of JEG-3 cells pretreated with k252a (lane 2) or k252b (lane 3) followed by 19 
32 
H2O2 and rhBDNF compared to cells treated with H2O2 and rhBDNF alone (lane 1). *p < 0.05, 1 
**p < 0.01.  2 
Table 1 
Patient characteristics.  
SGA: small for gestational age, PE: preeclampsia,  Values are the mean ± SEM and (range) or median value with [interquartile range]. 
    
Controls  




(n = 11) 
  
PE 
(n = 15) 
  
  
p value  
  
    
Controls vs 
normotensive SGA  
Controls 
 vs PE 
Normotensive 
SGA 
vs PE  

















Primipara (n) 3/16 6/11 13/15  - - - 

























n.s.  n.s.  n.s.  












p < 0.001 
  
 
p < 0.001 
  
Diastolic blood pressure 
(mmHg) 
65±2 





n.s.   p < 0.001 p < 0.001 








p < 0.001 
  
 












p < 0.01  p < 0.001 n.s.  
SGA (n) 0 11/11 11/15 - - - 
Gene Forward Reverse accession number 
TrkA 5’ - ACTGAGCTCTACATCGAGA 5’ - CTGCACAGTTTTCCAGGA NM_002529 
TrkB 5’ - AGAGGCTAAATCCAGTCCA 5’ - CAGGTTACCAACATCCCAA NM_006180 
TrkC 5’ - ATACTACCAAGAGGGAGAGA 5’ - TGGGTCACAGTGATAGGA NM_001007156 
NGF 5’ - ACTGAGGTGCATAGCGTA 5’ - GTGTCAAGGGAATGCTGA NM_002506 
BDNF 5’ - GTGAGAAGAGTGATGACCA 5’ - CTCTTCTATCACGTGTTCGA NM_170735 
NT-3 5’ - TGGCATCCAAGGTAACAACA 5’ - GGCAGGGTGCTCTGGTAAT NM_002527 
NT-4 5’ - CCCTCTCCTGAGATGTCA 5’ - GGAGGAGGAAAAGGAGGA NM_006179 
Table  2 

































































































Negative control Fetal membrane 
















First Second PE 









































r = -0.323, p = 0.037  
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